Company
Gilead Sciences
87 published works
Product Perspective: Complex Tort & Product Law
Gilead Tenofovir Cases: California Supreme Court Rejects Duty to Innovate or Accelerate Development of Alternatives to Non-Defective Products
By Hilda Akopyan, Malea Casillas, Magda Patitsas
Can a pharmaceutical manufacturer face liability for failing to bring an allegedly safer drug to market sooner, even when the drug it already sells is not defective? In Gilead Tenofovir…
Regulatory Oversight
Texas Reaches $45M Settlement With Gilead to Resolve Medicaid Kickback Allegations Over Patient-Support Programs
By Troutman Pepper Locke State Attorneys General Team
The state of Texas secured a $45 million settlement from Gilead Sciences Inc. over allegations that its patient-support programs improperly encouraged prescriptions for drugs covered by Medicaid. This case highlights…
Drug & Device Law
California’s Recent Gilead Decision Explains Why “Pre-Approval” Tort Claims Don’t, and Shouldn’t, Exist
By Bexis
Nearly a decade ago we published the blogpost “Pre-Approval Design Defects – No Such Thing.” As we discussed, “pre-approval” design (later joined by warning) claims were a transparent preemption dodge. …
Spicy IP
Mavyret Patent Abandonment Does Not Open the Field for Hepatitis C Generics
July 28, 2026 marked eight years of the National Viral Hepatitis Control Program (NVHCP). Launched under the National Health Mission, the program aims to eliminate Hepatitis C from India by…
Faeger Drinker on Products
California Supreme Court Rejects Duty to Innovate
On August 3, 2026, the California Supreme Court issued its decision in the closely watched Gilead Tenofovir Cases, No. S283862, — Cal.5th —, 2026 WL 2223748 (Cal. Aug. 3, 2026),…
Drug & Device Law
No Duty to Innovate: California Supreme Court Rejects New Negligence Theory
The California Supreme Court handed down its long-awaited decision in Gilead Tenofovir Cases yesterday, and as we hoped, the Court held that a drug manufacturer owes no duty of care…
The Virginia Defamation Law Blog
Virginia’s Vicarious-Liability Presumption Applies at Pleading Stage
Several years ago, this blog covered Garnett v. Remedi SeniorCare of Virginia, LLC, 892 F.3d 140 (4th Cir. 2018), in which the Fourth Circuit held that an employer could not…
In-House Ops
Goodwin’s Life Sciences Deal Flow Points to a More Selective M&A Market
By Corporate Counsel Business Journal
Life sciences M&A is back, but not as a free-for-all.Goodwin positions itself around a clear 2026 market signal: Life sciences M&A has reemerged as a competitive arena after a quieter…
Product Perspective: Complex Tort & Product Law
Gilead Tenofovir “Alternative Product” Duty at the CA Supreme Court: What It Means for Manufacturers
By Natalie Garcia Lashinsky, Ronald Tran, James Battle
A California Court of Appeal decision recognizing an unusual and potentially far-reaching negligence duty for product manufacturers is now before the California Supreme Court. In the Gilead Tenofovir Cases, the Court…
Drug & Device Law
California Supreme Court Hears Argument On The “Duty to Innovate”
We observed arguments last week in the California Supreme Court in Gilead Tenofovir Cases, and quality advocates on both sides put on a great performance. As we previewed last week,…